Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3K delta Inhibitors for Inflammation and Autoimmune Disease.
Cushing, T.D., Hao, X., Shin, Y., Andrews, K., Brown, M., Cardozo, M., Chen, Y., Duquette, J., Fisher, B., Gonzalez-Lopez de Turiso, F., He, X., Henne, K.R., Hu, Y.L., Hungate, R., Johnson, M.G., Kelly, R.C., Lucas, B., McCarter, J.D., McGee, L.R., Medina, J.C., San Miguel, T., Mohn, D., Pattaropong, V., Pettus, L.H., Reichelt, A., Rzasa, R.M., Seganish, J., Tasker, A.S., Wahl, R.C., Wannberg, S., Whittington, D.A., Whoriskey, J., Yu, G., Zalameda, L., Zhang, D., Metz, D.P.(2015) J Med Chem 58: 480-511
- PubMed: 25469863 
- DOI: https://doi.org/10.1021/jm501624r
- Primary Citation of Related Structures:  
4WWN, 4WWO, 4WWP - PubMed Abstract: 
The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochemical properties are described. This medicinal chemistry effort led to the identification of 1 (AMG319), a compound with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.
Organizational Affiliation: 
Department of Therapeutic Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.